Business

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

GEO-MVA Advancing as the Leading U.S.-Developed Mpox Vaccine Candidate ATLANTA, GA - April 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious disea...

articleGeovax Labs, Inc.April 24, 20253/company/geovax-labs-inc/news/geovax-responds-detection-clade-mpox-200253222
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

About this update from Geovax Labs, Inc.

[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"GEO-MVA Advancing as the Leading U.S.-Developed Mpox Vaccine Candidate","length":70,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - April 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today responded to the recent detection of Clade I Mpox viral particles in wastewater samples in Greenville, North Carolina - the first such identification in the state. This finding, disclosed by the North Carolina Department of Health and Human Services (NCDHHS), underscores the increasing threat posed by Clade I Mpox and the urgent need for expanded preparedness and Mpox vaccine availability.","length":593,"tagName":"p"},{"type":"text","content":"This development aligns with concerns raised by the Centers for Disease Control and Prevention (CDC), which continues to monitor Clade I Mpox - a more virulent strain associated with higher transmissibility and a greater case fatality rate than Clade II. Four confirmed Clade I Mpox cases have been reported in the U.S. to date - in California, Georgia, New Hampshire, and New York.","length":382,"tagName":"p"},{"type":"text","content":""The detection of Clade I Mpox in North Carolina wastewater is a warning shot - silent transmission may be occurring even before clinical cases are reported," said David Dodd, Chairman and CEO of GeoVax. "We encourage public health authorities to act decisively to expand our Mpox vaccine supply and ensure rapid, scalable access to effective solutions."","length":374,"tagName":"p"},{"type":"text","content":"GEO-MVA: A U.S.-Developed Vaccine Candidate at the Forefront of Biosecurity","length":75,"tagName":"p"},{"type":"text","content":"During this week's World Vaccine Congress in Washington, D.C., GeoVax's GEO-MVA vac...

More updates from Geovax Labs, Inc.

GeoVaxNorth CarolinaCladeClinical trialsvaccine availabilityvaccine supplywastewater samplesinfectious diseasesclinical casesDavid Doddbiotechnology company